Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

5 months ago Solid tumor , CAR-T

Successful CAR-T Treatment for Advanced Gastric Cancer! Beneficial for Liver Cancer, Brain Tumors, Pancreatic Cancer, with a DCR of 96.1%

Gastric Cancer

According to a report by People’s Daily on April 6, 2023, China has achieved another milestone in the CAR-T field. Recently, China Jiangxi Province successfully completed its first case of CAR-T cell therapy for solid tumors. This not only represents a significant breakthrough in new cancer treatment technologies in Jiangxi but also marks a major advancement in China’s CAR-T research and application.

China’s Jiangxi Achieves a Breakthrough in CAR-T Therapy for Solid Tumors

The patient, an advanced gastric cancer patient, had previously undergone chemotherapy combined with immune checkpoint inhibitor (ICI) treatment, but the disease was not well controlled. The tumor had widely metastasized to the abdominal cavity and multiple bones, accompanied by complications such as anorexia, abdominal distension, and severe recurrent reduction in blood cells, making the patient unable to tolerate chemotherapy.

With no other options, the patient received CAR-T cell reinfusion therapy on March 20, 2023, at the Oncology Center of The Second Affiliated Hospital of Nanchang University, with substantial support from the team at Peking University Cancer Hospital (Beijing Cancer Hospital). Fortunately, the patient has safely passed the peak period of cytokine release syndrome (CRS). Compared to before CAR-T treatment, tumor markers have decreased to normal levels, and the patient’s physical condition, mental state, and symptoms (such as abdominal distension and anorexia) have significantly improved. This marks a “zero breakthrough” for CAR-T cell therapy in solid tumors in Jiangxi Province of China, leaving a significant mark in the field of CAR-T research and application in China.

Peking University Cancer Hospital Showcases CT041 CAR-T at 2024 ASCO Conference with a Disease Control Rate of 96.1%

In addition to this fortunate case, the research team from Peking University Cancer Hospital showcased a domestically developed CAR-T product named “satri-cel” (development code CT041) at the recent 2024 American Society of Clinical Oncology (ASCO) conference. Satri-cel is a CAR-T cell therapy targeting Claudin18.2 (CLDN18.2) and is the only CLDN18.2 CAR-T cell therapy in the world approved for clinical trials (IND) in both China and the United States, targeting digestive tract tumors such as gastric cancer and pancreatic cancer.

The final results of the Phase 1 clinical trial (NCT03874897) were presented in an oral report at this conference. In patients with gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) treated with satri-cel monotherapy, the results showed a disease control rate (DCR) of 96.1% (49/51), an objective response rate (ORR) of 54.9% (28/51), a median overall survival (mOS) of 9.0 months, a median progression-free survival (mPFS) of 5.8 months, and a median duration of response (mDOR) of 6.4 months.

As early as May 2022, the team at Peking University Cancer Hospital had reported clinical cases of CT041 treating gastric cancer. A 57-year-old gastric cancer patient (Pt08), who had previously undergone three treatments, including PD-1 antibody, showed improvement after receiving CT041 CAR-T cell therapy. Visual inspection and CT scans indicated that the patient’s condition improved, with reduced umbilical tumor lesions, and the efficacy was still ongoing as of the date of the report.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CART #CancerTreatment #GastricCancer #LiverCancer #BrainTumor #PancreaticCancer #MedicalBreakthrough #Oncology #Jiangxi #ChinaBiotech #CancerResearch #ASCO2024 #PekingUniversityCancerHospital #InnovativeTherapy #MedicalAdvancements #HealthNews

5 months ago Myeloma

IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

IMWG

###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Global Breakthroughs

In the latest guidelines released by the International Myeloma Working Group (IMWG) in 2024, Equecabtagene Autoleucel, a CAR-T therapy independently developed in China, has been officially included. This marks the first and only Chinese CAR-T product included in the global treatment guidelines for relapsed and refractory multiple myeloma (RRMM). This milestone signifies a major breakthrough for China in the field of CAR-T therapy and brings new hope to RRMM patients worldwide.

####CARTTherapy: A New Hope for Multiple Myeloma Patients

Multiple myeloma (MM) is a challenging blood cancer to treat, with approximately 176,404 new cases and 117,077 related deaths globally in 2020. Traditional therapies have limited effectiveness for relapsed and refractory MM patients. The emergence of CAR-T cell therapy has brought significant treatment progress for this group. CAR-T therapy reprograms the patient’s own T cells to recognize and kill cancer cells, achieving remission rates of 73%-98%.

#### Equecabtagene Autoleucel: A Unique Fully Human CAR-T Product

Equecabtagene Autoleucel is the only fully human CAR-T product included in the “2024 IMWG RRMM CAR-T Guidelines.” Compared to the other two included CAR-T products, which are derived from mice and alpacas (ide-cel and cilta-cel), Equecabtagene Autoleucel’s unique design reduces immunogenicity while enhancing efficacy. Since its launch in China, it has demonstrated significant therapeutic effects and safety, with a total response rate of 98.9%, a complete response rate of 82.4%, and a one-year progression-free survival rate of 85.5%.

#### Global Recognition: The Significance of IMWG Guidelines

The IMWG guidelines are developed by top global experts in multiple myeloma, providing the latest research findings and best practice recommendations for CAR-T therapy. The “2024 IMWG RRMM CAR-T Guidelines” not only recognize the excellent efficacy of Equecabtagene Autoleucel but also offer detailed guidance on patient selection and safety management, covering the management of unique toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment.

#### Looking Ahead: Benefiting More Patients

The inclusion of Equecabtagene Autoleucel in the IMWG guidelines showcases China’s leading position in CAR-T therapy development and will help further expand its application globally. This achievement is a significant breakthrough for China’s biopharmaceutical field and brings new treatment hope for RRMM patients worldwide. With ongoing clinical research and real-world data accumulation, Equecabtagene Autoleucel is expected to benefit more patients domestically and internationally, continuously advancing CAR-T therapy.

In the global treatment landscape for multiple myeloma, Equecabtagene Autoleucel is at the forefront, bringing new hope to countless patients. Stay tuned to Equecabtagene Autoleucel and witness the outstanding innovation and global impact of China’s biopharmaceutical industry!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#EquecabtageneAutoleucel #CART #MultipleMyeloma #CancerTreatment #Biopharmaceuticals #IMWG2024 #MedicalBreakthrough #InnovativeTherapy #GlobalHealthcare #CancerResearch #PatientHope #ChineseMedicine #Immunotherapy

5 months ago CAR-T , Myeloma

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma

Multiple Myeloma

In recent years, CAR-T cell therapy has made groundbreaking progress in the field of relapsed/refractory multiple myeloma (RRMM), offering hope to patients struggling with limited treatment options. Recent data shows that Equecabtagene Autoleucel achieved an impressive complete response (CR) rate of 82.4% in Chinese clinical trials, garnering widespread attention for its outstanding efficacy.

### Breakthrough Research Findings

At the upcoming 50th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) in the UK, a study titled “Matching-Adjusted Indirect Comparison of Effective Characteristics Among Different BCMA Targeting CAR-T in Treatment of Relapsed or Refractory Multiple Myeloma (MAIC)” will be presented. This study compares the efficacy of four BCMA-targeted CAR-T products, revealing that Equecabtagene Autoleucel’s overall response rate (ORR) and CR rate are significantly superior to those of other comparators, especially in terms of CR rate.

### Clinical Performance of Equecabtagene Autoleucel

Equecabtagene Autoleucel is the world’s first fully human CAR-T product approved for marketing, having received priority review approval in China on June 30, 2023. The approval is based on results from the FUMANBA-1 Ib/II clinical study conducted across 14 centers in China. The study demonstrated that among 91 RRMM patients who had not previously received CAR-T therapy and had relapsed after multiple lines of treatment, Equecabtagene Autoleucel achieved a sCR/CR rate of 82.4%, with 97.8% of patients reaching minimal residual disease (MRD)-negative status.

### Pharmacodynamics and Pharmacokinetics Advantages

Compared to other BCMA-targeted CAR-T products, Equecabtagene Autoleucel shows significant advantages in pharmacodynamics and pharmacokinetics. Data indicates that Equecabtagene Autoleucel has a median time to response (TTR) of 15 days, and 62.3% of patients maintained CAR-T cell persistence for over 6 months. These findings suggest that Equecabtagene Autoleucel not only acts quickly but also remains effective in the body for an extended period, providing long-lasting therapeutic benefits.

### Structural Advantages Unveiled

Equecabtagene Autoleucel’s design includes unique structural advantages that minimize CAR-T cell exhaustion within the patient’s body. Research shows that Equecabtagene Autoleucel’s dissociation constant (Kd) is close to the natural dissociation kinetics of human T cells, with a dissociation time of about 6 minutes. This allows CAR-T cells to efficiently activate, kill, and proliferate within the body. In contrast, other BCMA-targeted CAR-T products have lower dissociation constants and longer dissociation times, which can lead to CAR-T cell exhaustion and reduced longevity.

### Long-Term Efficacy Outlook

Equecabtagene Autoleucel’s excellent performance in clinical trials brings new hope to RRMM patients. The long-term efficacy data in Chinese patients are particularly noteworthy. As time progresses, further clinical data will continue to validate Equecabtagene Autoleucel’s efficacy and safety, offering more effective treatment options for RRMM patients worldwide.

The success of Equecabtagene Autoleucel is not only due to its remarkable clinical efficacy but also the extensive scientific research and innovative technology behind it. This groundbreaking therapy sheds new light on the treatment of multiple myeloma and paves the way for future advancements in CAR-T cell therapy.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CART #MultipleMyeloma #EquecabtageneAutoleucel #CancerTreatment #Biopharmaceuticals #MedicalBreakthrough #Oncology #InnovativeTherapies #ClinicalResearch #HealthAdvancements

5 months ago CAR-T

One Year After Approval: How Effective is China’s First BCMA-Targeted CAR-T Therapy in Treating Multiple Myeloma?

### One Year After Approval: How Effective is China’s First BCMA-Targeted CAR-T Therapy in Treating Multiple Myeloma?

Multiple Myeloma

“In the past 20 years, the treatment of multiple myeloma has advanced rapidly, thanks in large part to the swift progress in drug development. Over the past year, China’s first independently developed and the world’s first fully human BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy was approved. In our real-world clinical applications, we have treated over 20 patients with an overall effectiveness rate of nearly 100%.”

On June 30, 2024, exactly one year after the approval of China’s first BCMA-targeted CAR-T therapy (Iquilonsen Injection), and also the world’s first fully human BCMA-targeted CAR-T therapy, how effective has the treatment been for patients? Professor Qiu Lugui, Director of the Lymphoma Treatment Center at the Chinese Academy of Medical Sciences Hematology Hospital, was interviewed by the People’s Daily Health Client.

“Multiple myeloma has a slow onset and early stages often show no obvious symptoms, making it easy to misdiagnose. To date, once diagnosed, the vast majority of patients experience one or more relapses, entering a refractory state, which is an incurable disease,” Professor Qiu Lugui told the People’s Daily Health Client.

Professor Qiu explained that current drugs for treating multiple myeloma fall into three categories: immunomodulators, proteasome inhibitors, and CD38 monoclonal antibodies. The indications for these drugs have gradually moved from refractory cases to frontline treatments, transforming multiple myeloma from a deadly disease with a median survival of around three years to a relatively controllable malignant hematological tumor with a median survival of 10 years or more after systematic multi-drug therapy.

CAR-T cell therapy is a cutting-edge technology for treating malignant hematological tumors. China’s independently developed fully human BCMA-targeted CAR-T drug (Iquilonsen Injection) is designed for multiple myeloma patients who have relapsed or whose disease remains uncontrolled despite traditional treatments including proteasome inhibitors and immunomodulators.

One particularly memorable case for Professor Qiu was a 70-year-old patient. “At that time, the patient was extremely weak and had already undergone all available treatments, including two types of immunomodulators, two types of proteasome inhibitors, CD38 monoclonal antibodies, and intensive chemotherapy, with no other effective options left,” recalled Professor Qiu. “However, the patient had a strong desire to live. Seeing his eager eyes, we couldn’t remain indifferent.”

“After confirming with the patient, we decided to proceed with the fully human BCMA-targeted CAR-T Iquilonsen therapy. One month after the treatment, the first evaluation showed complete remission. To date, the patient remains in complete remission,” said Professor Qiu.

“In real-world applications, we have treated over 20 patients with an overall effectiveness rate approaching 100%. However, due to the high cost of the drug and the fact that it is not covered by medical insurance, making the drug accessible remains a challenge,” Professor Qiu told the People’s Daily Health Client. “Currently, there are two methods to address this issue: one is to meet the needs of economically disadvantaged patients through commercial insurance; the other is to meet the needs of patients who meet the criteria for inclusion in CAR-T clinical research.”

“Additionally, in the year since the approval of China’s first CAR-T therapy for treating multiple myeloma, not only domestic patients but also patients from Europe, Asia-Pacific, Africa, and other regions have come to China for CAR-T treatment. Overall treatment driven by dynamic prognostic stratification will be the future path to cure for multiple myeloma patients both in China and globally,” said Professor Qiu.

#MultipleMyeloma #CARTTherapy #CancerTreatment #MedicalBreakthrough #BCMATargeted #ChinaHealthcare #InnovativeMedicine #PatientSuccess #GlobalHealth #Hematology #Immunotherapy

5 months ago CAR-T

Thérapie révolutionnaire apporte un nouvel espoir : le patient suisse Thomas commence le traitement CAR-T à l’hôpital Tongji de Wuhan

L’équipe du professeur Li Chunrui de l’hôpital Tongji de Wuhan a mené avec succès un cas de thérapie immunitaire à cellules T à récepteur antigénique chimérique (CAR-T) pour un patient atteint de myélome multiple récurrent et réfractaire, offrant une nouvelle vie au patient suisse Thomas.

Thomas, un patient suisse de 54 ans, lutte contre le myélome multiple depuis près de dix ans. Diagnostiqué pour la première fois en 2016, il a enduré de sévères douleurs osseuses et a subi plusieurs cycles de chimiothérapie systémique et de traitement par anticorps monoclonaux. Bien que son état ait été temporairement contrôlé, les rechutes répétées, dont la plus récente en 2022, ont rendu le traitement de plus en plus difficile.

Cependant, le développement mondial de la thérapie CAR-T a ravivé l’espoir. L’introduction du FUCASO (Eque-cel), le premier produit CAR-T entièrement humain en Chine continentale, a apporté une nouvelle lumière à Thomas. Ce traitement révolutionnaire présente non seulement une faible immunogénicité, mais offre également une efficacité prolongée, permettant aux patients de retrouver une qualité de vie élevée.

Thomas a finalement choisi de recevoir la thérapie CAR-T de pointe à l’hôpital Tongji, cherchant une percée fondamentale dans son traitement. La procédure d’aphérèse a été réalisée par l’équipe hématologique de premier plan de l’hôpital, qui possède une expertise de niveau international et met un accent particulier sur les besoins spécifiques des patients et la sécurité du traitement. Le médecin traitant a expliqué en détail le processus d’aphérèse lors d’une interview, déclarant : “Nous avons précisément collecté des cellules T du corps de Thomas, puis modifié ces cellules dans un environnement contrôlé pour cibler spécifiquement les cellules cancéreuses du myélome multiple. L’utilisation de FUCASO a grandement amélioré la spécificité et le taux de succès du traitement.”

Thomas a exprimé une reconnaissance et une appréciation élevées pour le professionnalisme de l’équipe hospitalière et la transparence du processus de traitement. L’hôpital Tongji a mis à profit sa technologie et ses équipements avancés pour offrir à Thomas une expérience d’aphérèse fluide et efficace, assurant une collecte de cellules T de haute qualité et ouvrant la voie au traitement ultérieur.

Thomas est maintenant rempli de confiance et d’anticipation, attendant avec impatience la nouvelle vie que promet la thérapie CAR-T. Ce nouveau départ marque une étape significative dans son parcours de traitement, injectant un nouvel espoir dans son chemin vers la guérison.

Nous continuerons à suivre le traitement ultérieur du patient et à en rendre compte.

#CART #MyelomeMultiple #FUCASOJourney #Equecel #HopitalTongji #SurvivantDuCancer #CancerDuSang #Immunotherapie #CARTEntierementHumain #TraitementDuCancer

5 months ago CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.

Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.

However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.

Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”

Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.

Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.

We will continue to follow up on the patient’s subsequent treatment and report on the progress.

CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment

5 months ago Myeloma , patient story

The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India

patient story

“Before coming to China for treatment, I was filled with worries. My condition was not optimistic, and I was afraid I might never see my family again… But after arriving here, everyone I met was so warm and welcoming. The doctors are not only professional but also incredibly patient. I am now truly, truly happy, and I will bring this gratitude back to India.” — Ms. Savita

This is the true story of Ms. Savita from India, a multiple myeloma patient. Her journey to seek medical treatment was long and arduous, and she was often moved to tears when recounting it.

In 2012, Savita was diagnosed with multiple myeloma in India. After undergoing various treatment methods, her condition relapsed, and doctors estimated she had only six months to live. Desperate and with nowhere else to turn, she decided to seek hope in China.

At the Jiangsu Provincial People’s Hospital North Branch, Savita successfully joined a clinical trial and underwent T-cell therapy. One month after treatment, evaluation results showed that her lesions had almost completely disappeared, indicating significant improvement.

When she was first admitted, Savita was bedridden, suffering from severe bone pain, and required daily injections of strong painkillers. Now, she can live like a healthy person and even went on a trip to Shanghai with her husband, Inder.

Even more joyful is the fact that her daughter will be getting married next January. Reborn with a new lease on life, she is filled with hope for the future, and her joy is palpable.

Savita’s husband, Inder, shared their medical journey in China with a group of multiple myeloma patients in India, and many are hopeful to come to China for treatment.

Ms. Savita’s story is a journey filled with hope and gratitude. She will bring this gratitude back to India, inspiring more people to see the light of hope.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#IndianPatient #ChinaTreatment #CancerRecovery #NewLife #Gratitude #MedicalMiracle #LightOfHope

5 months ago patient story , Myeloma

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

Patient story

Subtitle: Fighting for Love! A story of miraculous rebirth after all treatment options failed for a late-stage multiple myeloma patient in Thailand, who underwent CAR-T therapy in China.

Preface: When all treatment options had been exhausted, cancer progressed rapidly, and doctors regretfully said that Ms. M had no response to any medication. This situation could only lead to palliative care, meaning Ms. M had no chance to fight this disease anymore; her life was now on borrowed time. Fortunately, Ms. M’s family found new hope in China – CAR-T therapy. With the companionship of her family, Ms. M came to China and underwent the world’s first fully human BCMA CAR-T therapy. In just 22 days after treatment, all tumors miraculously disappeared, achieving complete remission (CR), and Ms. M was given a new lease on life!

In June 2021, the life of 58-year-old Ms. M experienced persistent back pain for over months. After detailed examinations at the hospital,resulting in a diagnosis of multiple myeloma. To quickly control the condition, Ms. M received treatments including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation.

In June 2023, the disease relapsed and Ms. M did not respond to any of these treatments. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless, indicating that Ms. M’s life was now on borrowed time! Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.

In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M.

On September 8, 2023, Ms. M finally officially entered the CAR-T treatment process. After all examination items met the requirements, single-cell collection was performed first.

Bridge therapy began on September 11, 2023;

Local radiotherapy to relieve bone pain started on September 24, 2023;

Fludarabine plus cyclophosphamide chemotherapy was administered from October 9-12, 2023;

Finally, on October 14, a small bag of milky-white liquid was infused into Ms. M’s body. The doctor said that inside were billions of “special” T cells that could precisely kill multiple myeloma cells. Once inside the body, they would initiate a mode of frenzied sweeping, wiping out cancer cells completely.

What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!

Every day now is precious to Ms. M. She can go shopping, chat with her family, enjoy delicious food with her family, and travel around the world with them, returning to the happy times before she fell ill. The only difference is that Ms. M and her family visit a fixed destination every month now – Shanghai, China. They have become accustomed to hearing the sacred announcement from the doctors here: no cancer in her body, continuing remission.

This is a microcosm of countless cancer patients overcoming the disease. The emergence of CAR-T cell therapy has brought new hope to cancer patients. I believe that in the future, more patients will be able to regain a new life like Ms. M.

Reference：

[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.

[2] 2023 IMS. P-290.

5 months ago patient story

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

Patient story

In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless.

Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.

In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M. What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!

Reference：

[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.

[2] 2023 IMS. P-290.

5 months ago Lymphoma , CAR-T

Participants in China’s CAR-T ‘Lymphoma Value-Based Payment Plan’ have achieved complete remission

🎗️ Participants in China’s CAR-T ‘Lymphoma Value-Based Payment Plan’ have achieved complete remission. 🎗️

Lymphoma

Exciting news! Fosun Kite has just announced that the first participants in China’s “Lymphoma Value-Based Payment Plan” have achieved complete remission. These four patients, hailing from Shanghai, Guangzhou, and Hangzhou, have all reached complete remission after undergoing the innovative CAR-T cell immunotherapy, bringing new hope to lymphoma treatment.

### Why is CAR-T Therapy So Important?

Lymphoma is a malignant tumor originating from the lymphatic hematopoietic system, with diffuse large B-cell lymphoma being the most common type. For many patients, traditional treatment methods may be limited, especially for those with refractory or early-relapsed disease. The advent of CAR-T cell therapy offers these patients a new treatment option.

### Innovative Payment Model: Value-Based Payment

Fosun Kite’s “Value-Based Payment Plan” is a groundbreaking initiative. Eligible patients who do not achieve complete remission after treatment can receive up to 600,000 RMB in financial reimbursement. This payment model not only alleviates the financial burden on patients but also ensures the effectiveness and value of the treatment.

### Success Stories from Initial Participants

At the First Affiliated Hospital of Zhejiang University School of Medicine, one of the initial participants achieved complete remission after receiving CAR-T therapy. Deputy Director Hu Yongxian explains that when lymphoma cells can no longer be detected in the patient’s body, it signifies complete remission (CR), which is crucial for long-term survival and cure.

### Future Prospects

Professor Zhu Zhigang believes this innovative payment model can benefit more patients and potentially facilitate the inclusion of CAR-T therapy in national health insurance, further enhancing medical accessibility. In the future, we hope to see more patients gain new life through this advanced treatment.

### Conclusion

The emergence of CAR-T cell therapy and the introduction of the “Value-Based Payment Plan” bring unprecedented hope to lymphoma patients. This is not only a breakthrough in medical technology but also an innovation in medical payment models. Let’s look forward to more patients benefiting from this advanced treatment and embarking on the path to recovery.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#Health #CancerTreatment #InnovativeTherapy #CART #FosunKite #Lymphoma #MedicalInnovation #CompleteRemission

6 months ago CAR-T

The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection

### 🚀 The Chinese medical team’s Revolutionary CAR-T Therapy: Long-lasting asthma relief with a single injection.!

asthma

📢 Exciting news from the world of medical science! The team led by Professor Peng Min at Tsinghua University has made a groundbreaking advancement in CAR-T cell therapy. Imagine a world where chronic diseases like allergic asthma can be managed with just a single injection. This could soon be a reality!

🌬 Asthma: A Global Challenge

Asthma is one of the most common respiratory diseases, affecting over 300 million people worldwide and causing approximately 250,000 deaths annually. Despite the availability of treatments, many patients require lifelong medication, which can be costly and burdensome.

💡 The Breakthrough Study

On May 27, 2024, the team published their findings in Nature Immunology. Their paper, titled A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice, introduces a novel CAR-T cell named 5TIF4. This engineered cell targets the factors that trigger allergic reactions. Remarkably, just one injection of 5TIF4 cells was enough to suppress signs and symptoms of allergic asthma in mice for an extended period.

🧬 How Does It Work?

Traditional therapies for chronic diseases often require repeated or lifelong administration. However, the 5TIF4 cells are designed to be long-lived and multifunctional. They can neutralize eosinophils (cells involved in allergic reactions) and block key pathways (IL-4 and IL-13 signaling) that drive asthma. This innovative approach not only targets the symptoms but also addresses the underlying causes of the disease.

🚧 Challenges and Solutions

While CAR-T therapy has revolutionized cancer treatment, applying it to non-cancerous diseases presents unique challenges:

**Targeting Non-Cancer Tissues**: Unlike tumors, affected organs like lungs in chronic diseases cannot be eliminated.
**Longevity of Therapy**: Chronic diseases are lifelong, necessitating long-lasting therapeutic cells.
**Safety**: Current CAR-T treatments often involve invasive procedures like chemotherapy, which are not suitable for chronic conditions.

Peng Min’s team overcame these hurdles by engineering CAR-T cells that do not require pre-treatment and can persist in the body, providing continuous protection against asthma.

💭 Future Prospects

The implications of this research are profound. If these results can be replicated in humans, we might see a new era where a single injection offers long-term relief from asthma. Moreover, the same principles could potentially be adapted to treat other diseases involving eosinophils and type 2 cytokines, such as allergies, atopic dermatitis, and eosinophilic esophagitis.

📰 Nature Immunology also highlighted this study in an article titled CAR T cells put the brakes on asthma, emphasizing the expanding scope of CAR-T therapy beyond cancer treatment.

🌟 Conclusion

This pioneering research by Tsinghua University marks a significant milestone in the fight against chronic diseases. With further clinical trials, we could be on the brink of a revolution in how we treat asthma and possibly other chronic conditions. Stay tuned for more updates on this exciting journey towards better health and wellness!

📸 Don’t forget to follow for more groundbreaking health news and updates!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#MedicalBreakthrough #CARTCellTherapy #AsthmaRelief #TsinghuaUniversity #HealthRevolution

6 months ago Myeloma , patient story

Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui

Заголовок: Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui

Владимир Борзёнков, 68-летний пациент из Санкт-Петербурга, Россия, недавно завершил ключевой этап терапии CAR-T — реинфузию — в международной больнице Jiahui в Шанхае. Этот важный шаг включает повторное введение Т-клеток, которые были генетически модифицированы для распознавания и атаки определённых раковых клеток, обратно в организм пациента. Для Владимира, который борется с заболеванием уже более пяти лет, этот этап имеет особое значение.

Перед реинфузией медицинская команда провела всестороннюю оценку его физического состояния, чтобы убедиться, что его организм сможет перенести процедуру. Несмотря на свой возраст, Владимир проявил твёрдую решимость и желание излечиться, что помогло ему преодолеть все возрастные препятствия. Его путь начался в декабре 2017 года с боли в пояснице, которая постепенно усиливалась в течение нескольких месяцев. К февралю 2018 года у него наблюдалось разрушение костей в нескольких местах, включая позвоночник, грудину и ключицу. Хотя этот период казался бесконечным испытанием, Владимир никогда не терял веру в жизнь. Сейчас, находясь на этом важном этапе, он полон надежды на будущее.

Для лечения больница Jiahui использовала FUCASO (Eque-cel), полностью человеческую CAR-T терапию, известную своей уникальной низкой иммуногенностью и длительной эффективностью, что предоставило пациенту терапевтические преимущества. Во время процедуры реинфузии больница Jiahui продемонстрировала передовые возможности в мониторинге и управлении побочными реакциями. Больница оснащена новейшими технологиями мониторинга и высококвалифицированной медицинской командой, что обеспечивает своевременное выявление и управление любыми потенциальными побочными реакциями, гарантируя безопасность и эффективность лечения. Этот высокий уровень мониторинга и внимательное отношение к здоровью пациента сделали процесс лечения Владимира не только эффективным, но и безопасным.

Благодаря своему опыту в международной больнице Jiahui Владимир ощутил мощный потенциал терапии CAR-T и значительные преимущества FUCASO. Теперь он полон надежды на будущие результаты лечения. Это лечение стало не только важной вехой в его личной борьбе с раком, но и демонстрирует мастерство Jiahui в технологии CAR-T и превосходное качество ухода за пациентами.

#CART #МножественнаяМиелома #ПутьFUCASO #Equecel #БольницаJiahui #Шанхай #ПобедительРака #ракКрови #Иммунотерапия #ПолностьюЧеловеческаяCART #ЛечениеРака

Menu

Tags Archives: CAR-T